Effect of Peptide Receptor Radionuclide Therapy on Somatostatin Receptor Status and  Glucose Metabolism in Neuroendocrine Tumors: Intraindividual Comparison of Ga-68 DOTANOC  PET/CT and F-18 FDG PET/CT

<table>Grouping based on the uptake of two PET/CTs. (a) Group A: a metastatic liver lesion presented both SMS (on the left) and FDG uptake (on the right). (b) Group B: a primary tumor in the pancreas head presented SMS uptake (on the left), FDG PET/CT images on the right showed no uptake in the primary. (c) Group C: a metastatic liver lesion presented FDG uptake (on the right) but was negative for somatostatin receptor expression (on the left).</table>

International Journal of Molecular Imaging

fig1

Figure 1

Figure 1: Effect of Peptide Receptor Radionuclide Therapy on Somatostatin Receptor Status and  Glucose Metabolism in Neuroendocrine Tumors: Intraindividual Comparison of Ga-68 DOTANOC  PET/CT and F-18 FDG PET/CT 

Figure 1 | Effect of Peptide Receptor Radionuclide Therapy on Somatostatin Receptor Status and  Glucose Metabolism in Neuroendocrine Tumors: Intraindividual Comparison of Ga-68 DOTANOC  PET/CT and F-18 FDG PET/CT 